Moderna Stock News

Moderna shared new data which shows that a 50 microgram dose of its booster vaccine increases the level of neutralizing antibodies 37-fold.

Modern described the findings as reassuring, but said it will also continue to develop an omicron-specific booster candidate.

(RTTNews) - Moderna, Inc. (MRNA) reported preliminary neutralizing antibody data against the Omicron variant following booster candidates at 50 g and 100 g dose levels. The currently authorized 50 g booster of mRNA-1273 increased neutralizing antibody levels against Omicron approximately 37-fold compared to pre-boost levels. A 100 g dose of

The company still plans to develop a vaccine specifically to protect against Omicron, which it hopes to advance into clinical trials early next year.

A THIRD dose of the Moderna vaccine offered a significant antibody response in the immune system in a "reassuring" trial.

The vaccine maker said the decision to focus on the current vaccine, mRNA-1273, was driven in part by how quickly the recently discovered variant is spreading

I expect a tidal wave of investing cash to move to this area of biotech due to Pfizer and Modernas success, and this part of the biotech sphere will benefit in the same way Tesla did. The post Investing in an Unreal 2022 appeared first on Money Morning Australia .

Pfizer Pushes Third Vaccine Dose For Kids 5 And Under As Pfizer and Moderna fight to get their COVID jabs approved for children under the age of 5, Pfizer revealed on Friday that it''s changing its approach by testing three vaccine doses in babies and preschoolers after discovering that two doses simply doesn''t provide enough protection. According to the AP , Pfizer announced the change after a preliminary analysis found 2- to 4-year-olds didnt have as strong an immune response as expected to the very low-dose shots the company is testing in the youngest children. All of this seems funny to us off the bat because it was our understanding that youngsters had natural immunity to the virus barring some immunodeficiency issue. Pfizer said it had expected data on how well the vaccines were working in children under 5 by year''s end. Now, nobody knows how long that might take as the company tries out different strategy. But one thing''s for sure: Pfizer is about to be selling a lot more vaccines.

Axiom Investors Bradley Amoils employs a clever process that has allowed the fund manager to find some early gems.

Maryland State Retirement & Pension System lifted its position in Moderna, Inc. (NASDAQ:MRNA) by 1.0% in the third quarter, Holdings Channel reports. The firm owned 25,804 shares of the companys stock after acquiring an additional 243 shares during the period. Maryland State Retirement & Pension Systems holdings in Moderna were worth $9,856,000 as of its []

Sinopharm vaccine have the least antibody response after three months compare to other vaccines, the latest antibody response for vaccines study done by a Sri Lankan research team shows. An antibody response research done by the Allergy Immunology and Cell Biology unit of University of Sri Jayewardenepura has shown that the antibody response was seen highest in the Moderna vaccine followed by Sputnik V, AstraZeneca, Sputink V light (first dose then) and then Sinopharm. The ACE2 blocking antibody levels were highest to lowest was Moderna > Sputnik V/ Oxford AstraZeneca (had equal levels)> first dose of Sputnik V (Sputnik light) > Sinopharm, the study said. Sinopharm is the most widely used vaccine in Sri Lanka which is generally believed to have contributed to lower levels of hospitalization and deaths, but its usefulness declines over time faster than others used in the country. In Sri Lanka recipients of all vaccines are being urged to get the Pfizer as a third booster which the government has made available.

Halbert Hargrove Global Advisors LLC acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 863 shares of the companys stock, valued at approximately $332,000. A number of other institutional []

Related Stocks: ANTM , TGT , CL , MCK , GS , BIIB , MRNA , KSS , SBUX , ZBRA , IPG , MMM , PG , LLY , HON , ADSK , MRK , HLT , MO , BBY , ODFL , HUM , HPQ , LOW ,

Moderna''s COVID Vaccine 4 Times More Likely To Cause Heart Inflammation Than Pfizer''s: Study Authored by Mimi Nguyen Ly via The Epoch Times, A study published in the British Medical Journal late Thursday suggests Moderna s COVID-19 vaccine is up to four times more likely to cause heart inflammationmyocarditis or myopericarditisthan Pfizer-BioNTechs COVID-19 vaccine. Vaccination with [Modernas vaccine] was associated with a significantly increased risk of myocarditis or myopericarditis in the Danish population, and the rate was threefold to fourfold higher with the Moderna vaccine compared to the Pfizer-BioNTech vaccine , authors said in the study, which spanned almost 85 percent of Danes, or 4.9 million people aged 12 and older. The increased risk of myocarditis or myopericarditis with the Moderna vaccine was primarily driven by an increased risk among individuals aged 12-39 years, said the researchers, from Denmarks Statens Serum Institute. The population-based cohort study , published Dec. 16 in the British Medical Journal (the BMJ), also corroborated previous studies and reports such as those from Israel and the United States that say there is an increased risk of myocarditis or myopericarditis with taking the mRNA-based Moderna or Pfizer vaccines.